IPP Bureau
Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib
By IPP Bureau - March 01, 2022
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Bruker releases CCS-Enabled TIMScore and TIMS DIA-NN 4D Proteomics Software
By IPP Bureau - March 01, 2022
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines
By IPP Bureau - March 01, 2022
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Synapse Medicine raises US $ 28 million to scale its medication reconciliation platform
By IPP Bureau - March 01, 2022
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical
By IPP Bureau - March 01, 2022
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Lupin launches Sevelamer Hydrochloride tablets in the United States
By IPP Bureau - March 01, 2022
Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg
Thermo Fisher Scientific extends partnership with Symphogen to support biopharma
By IPP Bureau - March 01, 2022
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
USFDA approves CITI Biopharma’s Vonjo
By IPP Bureau - March 01, 2022
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
By IPP Bureau - February 28, 2022
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
China’s NMPA accepts supplemental NDA for Carteyva
By IPP Bureau - February 28, 2022
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Unichem receives ANDA approval for bipolar disorder drug
By IPP Bureau - February 28, 2022
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
Europe clears blood test to predict Alzheimer’s disease
By IPP Bureau - February 28, 2022
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Cannabotech's IntegrativePain products reduce pain considerably
By IPP Bureau - February 28, 2022
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Mental wellness startup LISSUN opens centre in UP
By IPP Bureau - February 28, 2022
The company claims that this is the first time a mental wellness start-up has gone phygital in a Tier 2 city
Myonex acquires clinical trial and drug wholesale business of Hubertus in Berlin
By IPP Bureau - February 28, 2022
Clinical trial supply company strengthens its presence in the European Union
